Biotech News

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Aclaris Therapeutics (ACRS)Aclaris TherapeuticsConference / presentation

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday, September 10, 2026, at 2:45 PM ET, Aclaris’ Chief Executive Officer Dr. Neal Walker will participate in a fireside chat during the 2026 Cantor Global Healthcare Conference in New York, NY.

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com . The webcast will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn .

Aclaris Therapeutics Contact:

Will Roberts Senior Vice President Corporate Communications and Investor Relations (484) 329-2125 [email protected]

Related news

GPCRStructure Therapeutics2026-11-04 12:30 EST

Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference

ZURAZura Bio2026-08-31 20:30 EST

Zura Bio to Participate in the Cantor Global Healthcare Conference

XFORX4 Pharmaceuticals2026-09-09 11:00 EST

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

SABSSAB Biotherapeutics2026-10-14 12:30 EST

SAB BIO to Participate in Chardan 10th Annual Healthcare Conference

KNSAKiniksa2026-09-04 20:01 EST

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

CMMBChemomab Therapeutics2026-08-31 12:00 EST

Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference

VERAVera Therapeutics2026-10-02 13:24 EST

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026

HCMHUTCHMED2026-10-27 00:00 EST

Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer

ANABAnaptysBio, Inc.2026-09-01 20:15 EST

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

BMYBMYBristol-Myers Squibb Company2026-08-29 15:00 EST

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

Aclaris Therapeutics

Immuno-Inflammatory Drug Development Aclaris Therapeutics develops biologic and oral therapies for immuno-inflammatory diseases. Its portfolio targets upstream cytokines and intracellular signaling pathways. ATI-052 ATI-052 is a long-acting bispecific antibody against TSLP and IL-4 receptor alpha in proof-of-concept studies for asthma...

Recent company news

Stock data

Close
3.61 USD
Market cap
646.64M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States